Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?

Journal of Oncology

Volumn , Issue , 2013, Pages

  Atkins, Jordan J ^a   Appleton, Catherine M ^b   Fisher, Carla S ^c   Gao, Feng ^a   Margenthaler, Julie A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84905111737     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2013/964863     Document Type: Article

References (32)

1. Ismail-Khan R., Bui M. M., A review of triple-negative breast cancer. Cancer Control 2010 17 3 173 176 2-s2.0-77955010884
2. Rakha E. A., El-Sayed M. E., Green A. R., Lee A. H. S., Robertson J. F., Ellis I. O., Prognostic markers in triple-negative breast cancer. Cancer 2007 109 1 25 32 2-s2.0-33846266252 10.1002/cncr.22381
3. de Ruijter T. C., Veeck J., de Hoon J. P. J., van Engeland M., Tjan-Heijnen V. C., Characteristics of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology 2011 137 2 183 192 2-s2.0-78751607122 10.1007/s00432-010-0957-x
4. Lin N. U., Vanderplas A., Hughes M. E., Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology 2009 27 15, supplement, abstract 543
5. Perou C. M., Sørile T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Ress C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge Ø., Pergammenschlkov A., Williams C., Zhu S. X., Lønning P. E., Børresen-Dale A. L., Brown P. O., Botstein D., Molecular portraits of human breast tumours. Nature 2000 406 6797 747 752 2-s2.0-0034680102 10.1038/35021093
6. Dolle J. M., Daling J. R., White E., Brinton L. A., Doody D. R., Porter P. L., Malone K. E., Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiology Biomarkers and Prevention 2009 18 4 1157 1166 2-s2.0-66649101370 10.1158/1055-9965.EPI-08-1005
7. Millikan R. C., Newman B., Tse C. K., Moorman P. G., Conway K., Smith L. V., Labbok M. H., Geradts J., Bensen J. T., Jackson S., Nyante S., Livasy C., Carey L., Earp H. S., Perou C. M., Epidemiology of basal-like breast cancer. Breast Cancer Research and Treatment 2008 109 1 123 139 2-s2.0-42149134292 10.1007/s10549-007-9632-6
8. Carey L. A., Perou C. M., Livasy C. A., Dressler L. G., Cowan D., Conway K., Karaca G., Troester M. A., Chiu K. T., Edmiston S., Deming S. L., Geradts J., Cheang M. C. U., Nielsen T. O., Moorman P. G., Earp H. S., Millikan R. C., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Journal of the American Medical Association 2006 295 21 2492 2502 2-s2.0-33744960226 10.1001/jama.295.21.2492
9. Sorlie T., Tibshirani R., Parker J., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8418 8423 10.1073/pnas.0932692100
10. Abd El-Rehim D. M., Ball G., Finder S. E., Rakha E., Paish C., Robertson J. F. R., Macmillan D., Blamey R. W., Ellis I. O., High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. International Journal of Cancer 2005 116 3 340 350 2-s2.0-22244449596 10.1002/ijc.21004
11. Tischkowitz M., Brunet J. S., Bégin L. R., Huntsman D. G., Cheang M. C. U., Akslen L. A., Nielsen T. O., Foulkes W. D., Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007 7, article 134 2-s2.0-34547982817 10.1186/1471-2407-7-134
12. Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A., Lickley L. A., Rawlinson E., Sun P., Narod S. A., Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 2007 13 15 4429 4434 2-s2.0-34547661993 10.1158/1078-0432.CCR-06-3045
13. Fulford L. G., Easton D. F., Reis-Filho J. S., Sofronis A., Gillett C. E., Lakhani S. R., Hanby A., Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006 49 1 22 34 2-s2.0-33745660509 10.1111/j.1365-2559.2006.02453.x
14. Harris L. N., Broadwater G., Lin N. U., Miron A., Schnitt S. J., Cowan D., Lara J., Bleiweiss I., Berry D., Ellis M., Hayes D. F., Winer E. P., Dressler L., Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research 2006 8 6, article R66 2-s2.0-34248145042 10.1186/bcr1622
15. Mauri D., Pavlidis N., Ioannidis J. P. A., Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. Journal of the National Cancer Institute 2005 97 3 188 194 2-s2.0-13744257860 10.1093/jnci/dji021
16. Liedtke C., Mazouni C., Hess K. R., André F., Tordai A., Mejia J. A., Symmans W. F., Gonzalez-Angulo A. M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G. N., Pusztai L., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 2008 26 8 1275 1281 2-s2.0-41649102048 10.1200/JCO.2007.14.4147
17. Rouzier R., Perou C. M., Symmans W. F., Ibrahim N., Cristofanilli M., Anderson K., Hess K. R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J. S., Hortobagyi G. N., Pusztai L., Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research 2005 11 16 5678 5685 2-s2.0-23844549918 10.1158/1078-0432.CCR-04-2421
18. Yang W. T., Lam W. W. M., Cheung H., Suen M., King W. W. K., Metreweli C., Sonographic, magnetic resonance imaging, and mammographic assessments of preoperative size of breast cancer. Journal of Ultrasound in Medicine 1997 16 12 791 797 2-s2.0-0000202613
19. Sinn H. P., Schmid H., Junkermann H., Huober J., Leppien G., Kaufmann M., Bastert G., Otto H. F., Histological regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe und Frauenheilkunde 1994 54 10 552 558 2-s2.0-0028117972
20. El-Didi M. H., Moneer M. M., Khaled H. M., Makarem S., Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management. Surgery Today 2000 30 3 249 254 2-s2.0-0034071699
21. Huber S., Medl M., Vesely M., Czembirek H., Zuna I., Delorme S., Ultrasonographic tissue characterization in monitoring tumor response to neoadjuvant chemotherapy in locally advanced breast cancer (work in progress). Journal of Ultrasound in Medicine 2000 19 10 677 686 2-s2.0-0033770646
22. Yang W. T., Dryden M., Broglio K., Gilcrease M., Dawood S., Dempsey P. J., Valero V., Hortobagyi G., Atchley D., Arun B., Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Research and Treatment 2008 111 3 405 410 2-s2.0-51649117870 10.1007/s10549-007-9810-6
23. Herrada J., Iyer R. B., Atkinson E. N., Sneige N., Buzdar A. U., Hortobagyi G. N., Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clinical Cancer Research 1997 3 9 1565 1569 2-s2.0-0030769452
24. Helvie M. A., Joynt L. K., Cody R. L., Pierce L. J., Adler D. D., Merajver S. D., Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 1996 198 2 327 332 2-s2.0-0030044010
25. Keune J. D., Jeffe D. B., Schootman M., Hoffman A., Gillanders W. E., Aft R. L., Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. The American Journal of Surgery 2010 199 4 477 484 2-s2.0-77949907290 10.1016/j.amjsurg.2009.03.012
26. Huber S., Wagner M., Zuna I., Medl M., Czembirek H., Delorme S., Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Research 2000 20 1B 553 558 2-s2.0-0034027684
27. Esserman L. J., Hylton N., Yassa L., Barclay J., Frankel S., Sickles E., Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. Journal of Clinical Oncology 1999 17 1 110 119 2-s2.0-0032894301
28. Belli P., Costantini M., Malaspina C., Magistrelli A., LaTorre G., Bonomo L., MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clinical Radiology 2006 61 11 946 953 2-s2.0-33749055497 10.1016/j.crad.2006.07.004
29. Partridge S. C., Gibbs J. E., Lu Y., Esserman L. J., Sudilovsky D., Hylton N. M., Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. American Journal of Roentgenology 2002 179 5 1193 1199 2-s2.0-0036838972
30. Kwong M. S., Chung G. G., Horvath L. J., Ward B. A., Hsu A. D., Carter D., Tavassoli F., Haffty B., Burtness B. A., Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer Journal 2006 12 3 212 221 2-s2.0-33745125088 10.1097/00130404-200605000-00010
31. Guarneri V., Pecchi A., Piacentini F., Magnetic resonancy imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in Stage II-III breast cancer. Annals of Surgical Oncology 2011 18 8 2150 2157
32. Yeh E., Slanetz P., Kopans D. B., Rafferty E., Georgian-Smith D., Moy L., Halpern E., Moore R., Kuter I., Taghian A., Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. American Journal of Roentgenology 2005 184 3 868 877 2-s2.0-16244377095